Publications by authors named "A Kakrani"
Several COVID-19 vaccines were developed using different approaches to prevent both symptomatic COVID-19 cases and fatalities. The adults were vaccinated with two doses of AZD1222/Covishield ( = 77) [manufactured by Serum Institute of India Pvt Ltd] vaccine and BV152/Covaxin ( = 99) [manufactured by Bharat Biotech] vaccine. They were assessed for immune response at pre-vaccination, 1 month post first and 6 months post second dose for anti-SARS-CoV-2 IgG antibody, surrogate neutralizing antibody (NAbs), immune phenotypes, antigen specific NK, B and T cell response, their effector functionality by ELISPOT and plasma cytokine profile.
View Article and Find Full Text PDFBackground: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response is crucial for disease management, although diminishing immunity raises the possibility of reinfection.
Methods: We examined the immunological response to SARS-CoV-2 in a cohort of convalescent COVID-19 patients in matched samples collected at 1 and 6-8 months after infection. The peripheral blood mononuclear cells were isolated from enrolled study participants and flow cytometry analysis was done to assess the lymphocyte subsets of naive, effector, central memory, and effector memory CD4+ or CD8+ T cells in COVID-19 patients at 1 and 6-8 months after infection.
Article Synopsis
- Thrombocytopenia is a key issue in dengue, impacting platelets' activation and their interaction with blood vessel lining cells (endothelium), although the specific role of platelet-derived exosomes (PLT-EXOs) in this process is unclear.
- This study involved 28 healthy subjects and 69 dengue patients, examining platelet function and the characteristics of PLT-EXOs in relation to endothelial cell behavior.
- Results showed significant changes in platelet markers in dengue patients, with PLT-EXOs leading to damage in the endothelial cell layer and reduced levels of proteins essential for cell junction integrity, highlighting their potential role in dengue pathogenesis.
Earlier biomarkers of pulmonary tuberculosis (PTB) treatment outcomes are critical to monitor shortened anti-TB treatment (ATT). To identify early microbiologic markers of unfavorable TB treatment outcomes. We performed a subanalysis of 2 prospective TB cohort studies conducted from 2013 to 2019 in India.
View Article and Find Full Text PDF